Anwaar Saeed
Clinical trials sponsored by Anwaar Saeed, explained in plain language.
-
New Triple-Drug attack aims to shrink untreatable liver tumors
Disease control Recruiting nowThis study tests whether adding a targeted drug (zanzalintinib) to two immunotherapy drugs (durvalumab and tremelimumab) can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. About 40 adults who have not had prior systemic therapy will particip…
Phase: PHASE2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New hope for pancreatic cancer: triple-drug combo enters human testing
Disease control Recruiting nowThis early-phase study tests whether adding two new drugs (elraglusib and retifanlimab) to standard chemotherapy can help people with advanced pancreatic cancer that hasn't been treated before. The main goal is to check safety and find the right dose. Up to 12 adults will take pa…
Phase: PHASE1 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for advanced GI cancers: Triple-Drug combo trial launches
Disease control Recruiting nowThis study tests whether combining two or three drugs (cabozantinib, durvalumab, and tremelimumab) can safely shrink tumors in people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that cannot be removed by surgery will …
Phase: PHASE1, PHASE2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated May 12, 2026 13:42 UTC